Immunic Therapeutics
Immunic Therapeutics, founded in 2016 and headquartered in New York City, develops orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, with its lead program vidofludimus calcium (IMU-838) in advanced clinical trials for multiple sclerosis.
Services
Immunic Therapeutics specializes in the development of orally administered, small molecule therapies aimed at treating chronic inflammatory and autoimmune diseases. Their pipeline includes advanced-stage clinical trials for multiple sclerosis and preparatory phase 2 trials for celiac disease. Their lead development programs, vidofludimus calcium (IMU-838) and IMU-856, target specific inflammatory pathways and gastrointestinal conditions.
History
Founded in 2016, Immunic Therapeutics is headquartered in New York City with a subsidiary, Immunic AG, in Gräfelfing near Munich, Germany. The company has rapidly advanced its clinical pipeline, achieving significant milestones such as multiple phase 3 and phase 2 clinical trials. They are listed on the Nasdaq Stock Market under the ticker symbol 'IMUX'.
Lead Products
Immunic Therapeutics' lead product, vidofludimus calcium (IMU-838), is being tested for multiple sclerosis in both phase 3 and phase 2 clinical trials. It combines neuroprotective, anti-inflammatory, and anti-viral effects, showing a decrease in serum neurofilament light chain, indicating potential neuroprotective activity. The company is also developing IMU-856, targeting Sirtuin 6 (SIRT6), aimed at restoring intestinal barrier function and regenerating bowel epithelium, currently moving towards phase 2 clinical trials for celiac disease.
Pipeline and Clinical Trials
Immunic Therapeutics is conducting multiple clinical trials. Vidofludimus calcium is in phase 3 ENSURE trials for relapsing multiple sclerosis and the phase 2 CALLIPER trial for progressive multiple sclerosis. IMU-856 has shown positive results in a phase 1b clinical trial for celiac disease and is now in preparations for phase 2 trials. Additionally, IMU-381 is in preclinical testing for gastrointestinal diseases.
Recent Awards and Recognition
Immunic Therapeutics has received several awards for its innovative solutions. In 2023, they won the BioTech Breakthrough Award for 'Developmental Immunology Solution of the Year' for their IMU-856 program. The company also secured the German Stevie® Awards for 'Best Medical Event' and 'Best B2B Event' for their MS R&D webcast held in November 2022.